key: cord-0915746-rzx31qpg authors: Donina, Zh. A. title: Causes of Hypoxemia in COVID-19 date: 2022-03-05 journal: J Evol Biochem Physiol DOI: 10.1134/s0022093022010070 sha: a033287ef4f1f002a93a0c73f0e393ea73e09413 doc_id: 915746 cord_uid: rzx31qpg The global pandemic of a new coronavirus disease (COVID-19) has posed challenges to public health specialists around the world associated with diagnosis, intensive study of epidemiological and clinical features of the coronavirus infection, development of preventive approaches, therapeutic strategies and rehabilitation measures. However, despite the successes achieved in the study of COVID-19 pathogenesis, many aspects that aggravate the severity of the disease and cause high mortality of patients remain unclear. The main clinical manifestation of the new variant of SARS-CoV-2 virus infection is pneumonia with massive parenchymal lesions of lung tissue, diffuse alveolar damage, thrombotic manifestations, disruption of ventilation-perfusion relationships, etc. However, symptoms in patients hospitalized with COVID pneumonia show a broad diversity: the majority has minimal manifestations, others develop severe respiratory failure complicated by acute respiratory distress syndrome (ARDS) with rapidly progressing hypoxemia that leads to high mortality. Numerous clinical data publications report that some COVID pneumonia patients without subjective signs of severe respiratory failure (dyspnea, “air hunger”) have an extremely low saturation level. As a result, there arises a paradoxical condition (called “silent hypoxia” or even “happy hypoxia”) contradicting the very basics of physiology, as it essentially represents a severe life-incompatible hypoxemia which lacks respiratory discomfort. All this raises numerous questions among professionals and has already ignited a discussion in scientific publications concerned with the pathogenesis of COVID-19. Respiratory failure is a complex clinical problem, many aspects of which remain controversial. However, according to the majority of authors, one of the first objective indicators of the clinical sign of respiratory failure are hypoxemia-associated changes in external respiration. This review addresses some possible causes of hypoxemia in COVID-19. Committee on Taxonomy of Viruses assigned the infectious agent an official name SARS CoV 2 [1] . Coronaviruses (Coronaviridae) are a large fam ily of RNA containing viruses that can infect both animals and humans. In humans, coronaviruses can cause a range of diseases, from relatively mild acute respiratory infection (ARI) to severe acute respiratory distress syndrome (ARDS) [2, 3] . Large scale studies have found that airway epithe lial cells and mucosal immune cells are the first to become infected. Infected cells cause uncon trolled cascade expression of proinflammatory cytokines, chemokines and other mediators of the acute phase response, forming a "cytokine storm", an excessive immune response to infec tion [4] [5] [6] . COVID 19 differs from other forms of viral infections in that this variant of coronaviruses tar gets mainly the lungs, which is due to its tropism to lung tissue [7, 8] . To date, it has been shown that respiratory complications owing to a high sensitivity of the lungs to SARS CoV 2 virus are the main mortality factor in critically ill COVID 19 patients [9] [10] [11] . The reason for this sensitivity is that type II alveolar epithelial cells have a high level of expression of angiotensin converting enzyme 2 (ACE2), which is a receptor for SARS CoV 2, and type II transmembrane serine prote ase (TSP2), which promotes virus binding to ACE2 and penetration into the cell [12] [13] [14] . The available data indicate that ACE2 and TSP2 expressed on the surface of various airway, esoph ageal, intestinal, cardiac, adrenal, bladder, brain, and endothelial cells, as well as macrophages, may cause multiple organ failure [4, [7] [8] [9] [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] . As follows from the recent publications [22] [23] [24] [25] , patients admitted to an intensive care unit with severe ARDS and diagnosed with COVID 19 had a very low saturation level. However, despite the severity of life incompatible hypox emia, some patients had no signs of ARDS (tachypnea, dyspnea, "air hunger"). Subse quently, especially in elderly patients, there was a sharp and sudden deterioration of the condition, requiring emergency resuscitation measures. For example, a clinical observation report indicates that in a 64 year old patient with a positive coro navirus 2 (SARS CoV 2) test and ARDS progres sion, the saturation (SpO 2 ) measured by pulse oximetry was 68%, whereas the arterial oxygen tension (PaO 2 ) was 37 mm Hg with normocapnia (PaCO 2 41 mm Hg). In another, 74 year old, patient, also with a confirmed SARS CoV 2 result, during face mask oxygen breathing, SpO 2 was 62%, while PaO 2 was only 36 mm Hg. How ever, these patients had no complaints about breathing difficulties. From this, it follows that low saturation in the absence of visible respiratory discomfort is, in many cases, typical for most patients with COVID pneumonia [22, 26] . It should be noted that pulse oximetry (SpO 2 ), which is usually applied in medical practice for non invasive monitoring of hypoxemia, reflects only hemoglobin oxygen saturation (HbO 2 %) and thus mismatches the true partial oxygen pressure in arterial blood (PaO 2 ) [27] . However, according to the established ideas, the determinative factor of oxygen supply to tissues is not HbO 2 %, but PaO 2 in mm Hg. In compliance with the physio logical principles, oxygen dissociation from hemoglobin into blood depends primarily on the position of the oxyhemoglobin dissociation curve (ODC), which has a sigmoid shape, as well as on the oxygen carrying capacity of blood, blood flow rate, temperature factor, etc. [28] . For example, hypocapnia and respiratory alkalosis resulting from hyperventilation (tachypnea, hyperpnea) shift the dissociation curve leftward and thus increase hemoglobin affinity for oxygen, imped ing its getting into blood. This accounts for a higher SpO 2 level at a very low PaO 2 [29, 30] . As seen from the above clinical examples, regardless of measurement methods-be it a nonin vasive (pulse oximetry) or invasive PaO 2 determina tion in arterial blood, patients with COVID 19 pneumonia develop hypoxemia. Recently, in publications of many authors, the presence of hypoxia without appropriate signs of respiratory discomfort has been defined as "silent hypoxia" or "happy hypoxia" [22, 23, 31, 32] . The reports on "mysterious hypoxia" or "asymptomatic hypoxia" have risen a wide discussion in scientific publications covering in the light of the estab lished pathophysiological mechanisms the causes of ARDS absence in severe hypoxia at the early stage of COVID 19 [31, 33, 34] . It has been repeatedly shown in numerous studies that hypoxia progression in COVID 19 patients at the early stage of the disease occurs at the normal PaCO 2 level (normocapnia), which does not appear to be a sign of respiratory dysregulation [22, 23, 35] . However, hypoxia is known to cause hyperventilation leading to hypocapnia that inhibits central (medullary) chemoreceptors. As a result, the ventilatory response to hypoxia sub sides, thus explaining the absence of respiratory discomfort (dyspnea) in hypoxia. In this case, it is a respiratory dysregulation that is concerned. However, since ARDS develops at elevated CO 2 levels (hypercapnia), the corresponding symp toms of respiratory dysfunction may apparently show up at later stages of the disease, when, against the background of hypoxia and hypercap nia, critical respiratory failure develops, i.e. impaired respiratory biomechanics, increased air way resistance, disrupted ventilation perfusion relationships and pulmonary circulation, altered structure of the alveolar capillary membrane, thromboembolism, etc. [22, 33, 36] . It should be noted that respiratory failure, including latent respiratory failure, is a complex clinical problem, many aspects of which remain debatable. Hypoxemia is considered to be one of the objective indicators of respiratory failure [37] . When discussing the potential mechanisms of hypoxia in COVID 19, one should consider the direct effect of SARS CoV 2 virus on its cellular receptor (APF2), which is expressed in sensory cells of the carotid body, reducing the sensitivity of glomus cells to oxygen deficiency [38, 39] . It follows that one of the possible causes of hypox emia in COVID 19 patients may be inhibition of peripheral chemoreception [40] [41] [42] . Here, an important practical question arises about the amount of APP2 and TSP2 in the carotid body that suffices for SARS CoV 2 invasion into cells. The presence of APP2 in the carotid body was detected by immunoblotting [43, 44] , but other authors, based on the results of immunohisto chemical studies of the mouse carotid body, sug gest only a minimal expression of the APP2 receptor therein, in contrast to its massive expres sion by epithelial cells of the lungs, intestine and kidneys [40] . Therefore, the issue of the degree of involvement of the peripheral respiratory regula tion in the reflex mechanisms of hypoxemia development in COVID 19 has not been solved definitively as yet. However, reflex regulation does not rule out the direct influence of humoral shifts on the respiratory center. Possible neuroin vasion of SARS CoV 2 into the CNS is consid ered to be the cause of hypoxemia, although the exact localization of infected structures in the areas responsible for respiratory regulation and controlling respiratory sensations still remains largely undetermined [41, [45] [46] [47] . At the same time, the related coronaviruses SARS CoV and MERS CoV have been found in the brainstem respiratory neurons, leading to fatal outcomes due to the development of severe respi ratory failure [48] [49] [50] . It is quite likely that similar structures and neurotropism based infection mechanisms that were found for other coronavi ruses can be applied to SARS CoV 2 equally well [41, 42, [51] [52] [53] . Damage to the endothelium and lung microcir culatory bed is an important part of COVID 19 pathogenesis because SARS CoV 2 infects lung endothelial cells expressing APF2 [54] . It was established that acute inflammatory process and endothelial damage caused by the imbalance between procoagulant and fibrinolytic activities, elicits intravascular microthrombosis in small caliber pulmonary vessels [55] . Increased throm bosis has been detected in COVID 19 patients, while postmortem examination revealed massive damage to alveolar microcapillaries, edema and thickening of the alveolar capillary membrane, pulmonary capillary occlusion, presence of large thrombi causing pulmonary artery thrombosis [56] . These data indicate that with a severe clini cal course of COVID 19, thromboembolia is the most frequent complication that contributes to pulmonary vascular obstruction, disrupted venti lation perfusion relationships, and hypoxemia development [57] . Fibrin and thrombin deposition occurs mainly in the pulmonary microvasculatory bed, being a fac tor that promotes the development of ARDS and coagulopathy in patients dying from COVID 19. Since the transition of oxygen from alveolar air to the blood of pulmonary microvessels occurs by diffusion across the alveolar capillary membrane, its thickening, as well as microvascular thrombi, can lead to decreased oxygen diffusing capacity (D LO2 ) and the development of arterial hypox emia. It has been shown that in severe ARDS, there occurs alveolar and interstitial edema result ing from increased permeability of endothelial and alveolar epithelial barriers of pulmonary cap illaries, causing infiltration of fluid rich in protein and immune cells into the parenchyma [58] . Fluid accumulation in the alveoli, impaired sur factant synthesis promoting alveolar collapse-all these events reduce the efficiency of gas exchange between the alveoli and vasculature, leading to alveolar hypoxia and hypoxemia [59] . Therefore, microvascular endothelial damage and dysfunc tion of some alveoli are also the factors that posi tively correlate with the development of hypoxemia, particularly in severely ill patients with lower respiratory tract lesions. Some authors consider oxidative stress as one of the possible factors of severe COVID 19 [60] . The relationship has been established between inflam mation and oxidative stress [61] , but many issues concerned with the degree of oxidative stress involvement in the cytokine storm have not yet been sufficiently studied. Meanwhile, it is sug gested that COVID 19 may entail the dysfunction of both endothelial and platelet mitochondria, which may influence thrombosis [62] . Computer simulations have only provided ten tative data on the mechanism of SARS CoV 2 impact directly on the hemoglobin heme group [7, 63] . It is hypothesized that SARS CoV 2 does not interact with erythrocytes directly, but affects them through an additional receptor CD147. Molecular analysis of the SARS CoV 2 structure showed that ORF8 protein and surface glycopro tein of the virus can bind to porphyrin, while ORF1ab, ORF10 and ORF3a proteins can inter act with the 1 β chain of hemoglobin resulting in dissociation of iron and porphyrin molecules. Dysfunctional hemoglobin deprived of iron atoms is unable to perform the gas transporting function (O 2 and CO 2 transport), leading to a reduced effi ciency of gas exchange and aggravated hypoxia [64, 65] . As for the causes of hypoxemia without dyspnea manifestation, not all authors mention that "silent" hypoxemia can occur not only in COVID 19, but also in patients with atelectasis, intrapulmonary or intracardiac shunt [66] . As is known, the adequacy of gas exchange depends primarily on ventilation perfusion relationships, i.e. the balance between capillary blood flow and pulmonary ventilation. As some authors rightly point out, the key factor of hypoxemia develop ment at an early stage of SARS CoV 2 infection is a mismatch between the ventilation perfusion ratio (V/Q) and the presence of anatomic arterio venous anastomoses or alveolar shunts in the lungs [67] [68] [69] [70] [71] . Right to left shunting implies the passage of part of venous blood through a shunt, bypassing ventilated areas of the lungs. Thus, with increased fraction of the pulmonary shunt frac tion, hypoxemia results from partial discharge of unoxygenated venous blood (venous admixture) into the arterial bed [69] . An intrapulmonary right to left shunt has been demonstrated during contrast echocardiography in a patient with COVID 19 [72] , when shunting was accompa nied by hypoxia and a corresponding increase in lung ventilation. However, in the presence of a shunt, hyperventilation did not increase PaO 2 , but decreased PaCO 2 , since CO 2 has higher diffu sion capacity than O 2 . Consequently, in this case, hypocapnia can develop without an increase in ventilation, which accounts for the absence of dyspnea in hypoxemia. In the case of aggravating ARDS severity with progressing hypoxemia and increasing PaCO 2 , dyspnea with corresponding manifestations of respiratory discomfort may probably develop. In conclusion, it is worth mentioning that this review article was focused on the analysis of some mechanisms of hypoxemia in ARDS, caused by a new coronavirus infection SARS CoV 2. The factors described herein are links of the same chain and are of crucial importance for the devel opment of hypoxemia in COVID 19. Obviously, SARS CoV 2 neuroinvasion into the peripheral and central respiratory chemoreceptors comes to the forefront. The further development of disor ders results from a complex influence of the endo thelial damage in the lung microcirculatory bed, massive alveolar lesion, impaired hemoglobin molecules, etc. However, according to many authors, the leading role in the development of hypoxemia in the absence of dyspnea belongs to intrapulmonary shunting. Further studies will hopefully reveal additional mechanisms of hypox emia development and its involvement in the pathogenesis of COVID 19. This work was supported by the Federal budget within a governmental assignment to the Pavlov Institute of Physiology. The authors declare that they have no conflict of interest related to the publication of this article. COVID 19 case fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country level Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore Advancing towards precision medicine in ARDS Innate immune and inflammatory responses to respiratory viruses Immune response to SARS CoV 2 and mechanisms of immunopathological changes in COVID 19 Review: Cyto kine storm syndrome: Looking toward the preci sion medicine era COVID 19: Attacks the 1 Beta chain of hemoglobin and captures the por phyrin to inhibit human heme metabolism ChemRxiv Epub ahead of print Cytokine storm intervention in the early stages of COVID 19 pneumonia Angiotensin converting enzyme 2 (ACE2) as a SARS CoV 2 receptor: molecular mechanisms and potential therapeutic target Tackling the cytokine storm in COVID 19, challenges and hopes Association between hypoxemia and mortality in patients with COVID 19 Cell entry mechanisms of SARS CoV 2 Functional assessment of cell entry and receptor usage for SARS CoV 2 and other lineage B betacoronavi ruses Receptor recognition by the novel corona virus from Wuhan: An analysis based on decade long structural studies of SARS coronavirus Severe acute respiratory syndrome A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus induced lung injury Human immuno pathogenesis of severe acute respiratory syndrome (SARS) Characterization of cytokine/chemokine profiles of severe acute respi ratory syndrome Clinical fea tures of patients infected with 2019 novel corona virus in Wuhan Endothelial cell infection and endotheliitis in COVID 19 Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases Basing respiratory management of coronavirus on physiological principles The patho physiology of "happy" hypoxemia in COVID 19 The standard of care of patients with ARDS: ven tilatory settings and rescue therapies for refractory hypoxemia Silent hypoxia: a harbinger of clinical dete rioration in patients with COVID 19 The infection that's silently kill ing coronavirus patients. The New York Times Working accuracy of pulse oximetry in COVID 19 patients stepping down from intensive care: a clinical evaluation Analysis of factors which affect the relationship between inspired oxygen partial pressure and arterial oxygen satura tion The oxygen dissociation curve: quantifying the shift Modulation of Hb O 2 affinity to improve hypox emia in COVID 19 patients COVID 19 with silent hypoxemia. Tidsskr Den Nor Laege forening 140 The mystery of the pan demic's "happy hypoxia COVID 19 pneumonia: ARDS or not? Silent hypoxaemia in COVID 19 patients Severe Hypox emia in Early COVID 19 Pneumonia Lung pathology of fatal severe acute respiratory syn drome Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneu monia Adaptation to chronic hypoxia involves immune cell invasion and increased expression of inflammatory cytokines in rat carotid body Expressions of angiotensin and cytokine receptors in the paracrine signaling of the carotid body in hypoxia and sleep apnea SARS CoV 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Can we use interleukin 6 (IL 6) blockade for coronavirus disease 2019 (COVID 19) induced cytokine release syndrome (CRS)? Brainstem involve ment and respiratory failure in COVID 19 Angiotensin and carotid body chemo reception in heart failure Mino Kenudson M (2021) Lung histopathology in COVID 19 as compared to SARS and H1N1 influenza: a systematic review Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China A first case of meningitis/encephalitis asso ciated with SARS Coronavirus 2 Central nervous system involve ment by severe acute respiratory syndrome coro navirus 2 (SARS CoV 2) Lethal infection of K18 hACE2 mice infected with severe acute respiratory syndrome coronavirus Severe acute respiratory syn drome coronavirus infection causes neuronal death in the absence of encephalitis in mice trans genic for human ACE2 Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice trans genic for human dipeptidyl peptidase 4 Neurotropism of human coro navirus 229E Mechanisms of host defense following severe acute respiratory syndrome coronavirus (SARS CoV) pulmonary infection of mice Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Incidence of thrombotic complications in critically ill ICU patients with COVID 19 Autopsy findings and venous thromboem bolism in patients with COVID 19: a prospective cohort study Man nose binding lectin is associated with thrombosis and coagulopathy in critically ill COVID 19 patients Pneumonia, acute respiratory dis tress syndrome, and early immune modulator therapy Mecha nisms of hypoxemia Redox biology of respiratory viral infections Pulmonary Vascu lar Endothelialitis, Thrombosis, and Angiogenesis in COVID 19 Mitochondria in lung disease COVID 19 Dis ease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin COVID 19: hemoglobin, iron, and hypoxia beyond inflam mation. A narrative review Mitochondria in lung disease Using measurements of shunt and ventila tion to perfusion ratio to quantify the severity of bronchopulmonary dysplasia Respiratory failure, mechanisms of abnormal gas exchange, and oxygen delivery Respiratory physiology-the essentials Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID 19 Dyspneic and non dyspneic (silent) hypoxemia in COVID 19: possible neuro logical mechanism Autopsy findings and venous thromboem bolism in patients with COVID 19: a prospective cohort study Severe COVID 19 disease: rather AVDS than ARDS?